Sotera Health Co 8-K

What Happened

• On May 20, 2026 Sotera Health Company filed an 8-K reporting Amendment No. 7 to its First Lien Credit Agreement (originally dated December 13, 2019) with JPMorgan Chase Bank, N.A. as First Lien Administrative Agent and the 2026 Refinancing Term Lenders.
• The Amendment provides for Repriced Term Loans to Sotera Health Holdings, LLC in an aggregate principal amount of $1,415,914,725.62, reduces the interest rate spread by 0.25% across term loans, and sets the applicable margin for the Repriced Term Loans at Adjusted Term SOFR + 2.25% (0.00% floor), with alternate rate election options.

Key Details

• Principal amount of Repriced Term Loans: $1,415,914,725.62.
• Interest margin: Adjusted Term SOFR + 2.25% (0.00% floor); Company may elect Alternate Base Rate + 1.25% or Adjusted Daily Simple SOFR + 2.25%.
• Spread reduction: 0.25% decrease across term loans under the facility.
• Amortization and term: 1.00% annual amortization; maturity date May 30, 2031.
• Other economics: 1.00% “soft call” premium applies to certain repricing transactions occurring within six months after the Amendment’s effective date.

Why It Matters

• The Amendment lowers Sotera’s effective borrowing cost modestly (0.25% spread reduction), which should reduce interest expense versus prior terms if rates remain similar, improving near-term cash flow.
• The new Repriced Term Loans establish a material, long-term financial obligation (maturing 2031) that investors should track as part of the company’s capital structure and debt service requirements.
• The 1% amortization and soft-call premium affect the pace of principal repayment and the cost to refinance again within six months, which are relevant to refinancing flexibility and future financial planning.